Network News
The National Medical Products Administration (NMPA) in China has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vitro diagnostic device in China. It is intended as a companion diagnostic to identify patients with MSI-high (MSI-H) solid tumors for treatment with KEYTRUDA® (pembrolizumab), the anti-PD-1 therapy from Merck & Co., Inc., […]
read more
aimed analytics GmbH highlighted in deutsche-startups.de
5 neue Startups: ONOX, aimed analytics, Recarbox, FORMIC, showroom.fm Es ist wieder soweit – neue Startups stehen in den Startlöchern! Hier sind einige spannende junge Unternehmen, die man kennen sollte. Heute werfen wir einen Blick auf diese Neugründungen: ONOX, aimed analytics, Recarbox, FORMIC und showroom.fm. deutsche-startups.de stellt heute erneut eine Auswahl junger Startups vor, die […]
read more
BioMed X Launches First Research Project in Partnership with the Government of Barbados to Advance Therapy of Early Diabetic Kidney Disease
Bridgetown, Barbados, January 27, 2026 – BioMed X, a leading innovation hub for pharma, today announced the launch of its first research project in partnership with the Government of Barbados and with support from the European Union’s PharmaNext Programme. The new global call for research proposals, entitled “AI-Enabled Therapy of Early Diabetic Kidney Disease in Barbados,” addresses one of the most pressing and underexplored […]
read more
Natural and safe contraception: New research consortium aims to enable more reliable home testing
The German Federal Ministry of Research, Technology, and Space is providing €2.8 million in funding for an interdisciplinary scientific consortium with the aim of making cycle apps for determining a woman’s fertile and infertile days significantly more reliable by taking biological markers into account. Researchers from the universities and university hospitals of Düsseldorf, Hamburg, and […]
read more
Heidelberg Pharma Received Development Milestone Payment from Partner Takeda
Ladenburg, Germany, 29 January 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that it has received a milestone payment under the terms of its license agreement with partner Takeda based on the achievement of a clinical development milestone for Takeda’s investigational medicine that utilizes […]
read more
ERC Funding for Hellmut Augustin and Michael Platten
Scientists receive Proof of Concept Grants to develop the application potential of their research results In order to develop the application potential of their research results, Prof. Dr Hellmut Augustin and Prof. Dr Michael Platten are receiving funding from the European Research Council (ERC) that the ERC makes available as Proof of Concept Grants. Hellmut Augustin […]
read more
RHEACELL makes second location in Heidelberg visible
Heidelberg, January 28, 2026 – RHEACELL GmbH & Co. KG is continuing to expand its presence in Heidelberg and moved into a second location in the Pfaffengrund district in August last year. At the start of the year, the location is now also becoming visible to the outside world: this week, the company logo will […]
read more
TUM Researchers receive two ERC Grants
The European Research Council’s (ERC) Proof of Concept Grants are designed to help researchers turn their findings into real‑world innovations. Two ERC‑funded follow‑up projects at TUM will each receive approximately 150,000 euros in support. The projects focus on virus‑driven cancer treatments and new ways to supply electrons for enzyme‑based technologies. Researchers at TUM have secured […]
read more
Highly endowed research award for DKFZ scientist
Daniel Kirschenbaum from the German Cancer Research Center (DKFZ) is developing new methods to find out exactly how immune cells are suppressed by malignant brain tumors. He is being supported in this by the EACR-Mark Foundation and the Pezcoller Foundation with the Rising Star Award, which is endowed with 100,000 euros. Tumor cells have a […]
read more
